Kelyniam Acquires Cranston Holdings, LLC

CANTON, Conn.--(BUSINESS WIRE)--Kelyniam Global, Inc. (OTC: KLYG), an emerging medical device manufacturing company that recently was granted FDA 510(k) approval, announced today that it will acquire Cranston Holdings, LLC. Cranston Holdings, LLC has rapid prototyping operations in Connecticut, and its employees have tremendous knowledge and expertise in Stereolithography and multiple aspects of rapid prototyping for the medical industry. Kelyniam is a pioneer in the production of custom cranial implants utilizing computer aided design and computer aided manufacturing of advanced medical grade polymers. This addition significantly strengthens Kelyniam’s position in the medical device space and positions them as a company to watch.

“We are pleased to join the Kelyniam team, and are excited about what we have seen with how dynamic Kelyniam can be implementing processes and controls. This is a great marriage of two companies that both have exceptional technology and capabilities.”

“This acquisition will immediately add additional shareholder value by integrating Cranston’s employees and equipment into our infrastructure,” said James Ketner, president and CEO of Kelyniam. “Most importantly, Cranston owns an in-house developed proprietary software package that will assist us in our ISO 13485, 21 CFR 820 compliance, and that software package is now IP of Kelyniam.”

Chris Breault, former president of Cranston Holdings, LLC, stated, “We are pleased to join the Kelyniam team, and are excited about what we have seen with how dynamic Kelyniam can be implementing processes and controls. This is a great marriage of two companies that both have exceptional technology and capabilities.”

Mr. Breault will be joining Kelyniam’s Board of Directors, and will be in charge of Operations at Kelyniam’s new Engineering and Manufacturing facility in Canton Connecticut.

Cranston Holdings had revenues in 2010 of approximately $600,000 USD. The acquisition is for an equity swap for assets and revenues.

About Kelyniam Global, Incorporated

Kelyniam Global (OTC: KLYG), Inc. specializes in the use of CAD/CAM technology to provide patient specific custom implants to assist medical professionals by allowing them to operate more effectively, improve patient care, and reduce health care costs by providing the highest quality products available with today's technology. The company is continually researching and developing new products and processes to help patients live more active and productive lives.

Please visit our website at www.kelyniam.com for more information.

Forward-Looking Statements

Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as "anticipate," "believes," "estimate," "expect," "should," "intend," "projects," "objective" and "appears" and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the impact of competitive products and pricing; capacity and supply constraints or difficulties; product development, commercialization or technological difficulties; the regulatory and trade environment; the impact of reimbursement rates and coverage; and the risk factors reported from time to time in the Company's SEC reports. The Company undertakes no obligation to revise any forward-looking statements as a result of future events or developments.